<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Toxics</journal-id><journal-id journal-id-type="iso-abbrev">Toxics</journal-id><journal-id journal-id-type="publisher-id">toxics</journal-id><journal-title-group><journal-title>Toxics</journal-title></journal-title-group><issn pub-type="epub">2305-6304</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39997927</article-id><article-id pub-id-type="pmc">PMC11860412</article-id>
<article-id pub-id-type="doi">10.3390/toxics13020112</article-id><article-id pub-id-type="publisher-id">toxics-13-00112</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Apigenin Induces Apoptosis and Inhibits Migration in Human Cholangiocarcinoma Cells</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kaewmanee</surname><given-names>Mayurachat</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af1-toxics-13-00112" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0827-4375</contrib-id><name><surname>Limpaiboon</surname><given-names>Temduang</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af2-toxics-13-00112" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Ngernyuang</surname><given-names>Nipaporn</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-toxics-13-00112" ref-type="aff">1</xref><xref rid="af2-toxics-13-00112" ref-type="aff">2</xref><xref rid="af3-toxics-13-00112" ref-type="aff">3</xref><xref rid="c1-toxics-13-00112" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Katalini&#x00107;</surname><given-names>Maja</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-toxics-13-00112"><label>1</label>Chulabhorn International College of Medicine, Thammasat University, Pathumthani 12120, Thailand; <email>may_mtmu@yahoo.com</email></aff><aff id="af2-toxics-13-00112"><label>2</label>Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Science, Khon Kaen University, Khon Kaen 40002, Thailand; <email>temduang@kku.ac.th</email></aff><aff id="af3-toxics-13-00112"><label>3</label>Thammasat University Research Unit in Biomedical Science, Thammasat University, Pathumthani 12120, Thailand</aff><author-notes><corresp id="c1-toxics-13-00112"><label>*</label>Correspondence: <email>nngernyuang@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>13</volume><issue>2</issue><elocation-id>112</elocation-id><history><date date-type="received"><day>31</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>20</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>28</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Cholangiocarcinoma (CCA) is a rare and highly aggressive cancer of the biliary tract, associated with poor clinical outcomes due to late diagnosis, extensive metastasis, drug resistance, and limited treatment options. Apigenin, a natural flavonoid, has been found to exhibit anticancer properties in several types of human cancer cells. Therefore, apigenin may be relevant to developing chemotherapeutic agents for cancer treatment. In this study, we examined the effects of apigenin on cell viability, cell cycle distribution, apoptosis, and cell migration in human CCA cell lines (KKU-M055) under <italic toggle="yes">in vitro</italic> conditions. The results demonstrate that apigenin significantly suppressed specific CCA cell proliferation by inducing cell cycle arrest at the G2/M phase and promoting cell apoptosis in KKU-M055 cells while exhibiting low toxicity in immortalized MMNK1 cells. Apigenin enhanced apoptotic features, including nuclear fragmentation and the loss of mitochondrial membrane potential. Furthermore, apigenin induced the apoptosis of KKU-M055 cells in both extrinsic and intrinsic pathways by activating caspase-8, -9, and -3/7. Moreover, apigenin inhibited KKU-M055 migration. Our study suggests apigenin as a promising candidate for treating CCA, and these findings provide theoretical support for the further development and potential application of apigenin in clinical CCA therapy.</p></abstract><kwd-group><kwd>apigenin</kwd><kwd>anticancer</kwd><kwd>cholangiocarcinoma</kwd><kwd>apoptosis</kwd><kwd>anti-migration</kwd></kwd-group><funding-group><award-group><funding-source>Thailand Science Research and Innovation (TSRI) Fundamental Fund</funding-source><award-id>2567</award-id></award-group><award-group><funding-source>Thammasat University</funding-source></award-group><funding-statement>This research is supported by the Thailand Science Research and Innovation (TSRI) Fundamental Fund, fiscal year 2567, and Thammasat University.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-toxics-13-00112"><title>1. Introduction</title><p>Cholangiocarcinoma (CCA) is a hepatobiliary cancer that is extremely aggressive and originates from the epithelial cells of the bile ducts. Although CCA is rare worldwide, one report indicated high incidence rates in East and Southeast Asia, particularly in northeast Thailand [<xref rid="B1-toxics-13-00112" ref-type="bibr">1</xref>]. In Thailand, the primary risk factor of CCA is infection with the liver fluke <italic toggle="yes">Opisthorchis viverrini</italic> (OV), which is a carcinogen that causes the normal bile duct to transform into a tumor [<xref rid="B2-toxics-13-00112" ref-type="bibr">2</xref>]. It has been difficult to detect and diagnose CCA early since the disease frequently manifests at an advanced or locally advanced stage. The only potentially curative treatment for CCA patients is surgical resection, but most patients are not eligible for this procedure because their condition is advanced at diagnosis [<xref rid="B3-toxics-13-00112" ref-type="bibr">3</xref>]. In recent years, treatment strategies for advanced CCA have been explored, including chemotherapy, radiotherapy, and combination chemoradiotherapy. The standard recommended treatment for unresectable or advanced CCA consists of a combination of gemcitabine and cisplatin (GC). This regimen has been shown to improve both overall survival (OS) and progression-free survival (PFS) compared to gemcitabine or cisplatin alone [<xref rid="B4-toxics-13-00112" ref-type="bibr">4</xref>]. However, this treatment often causes side effects due to damage to the surrounding healthy tissues or organs. Moreover, the long-term prognosis of CCA patients treated with systemic GC treatment remains poor due to drug resistance [<xref rid="B5-toxics-13-00112" ref-type="bibr">5</xref>]. Therefore, developing innovative treatment drugs is important for improving the survival rates of CCA patients. For over half a century, bioactive phytochemical compounds have been essential in cancer chemotherapy and chemoprevention [<xref rid="B6-toxics-13-00112" ref-type="bibr">6</xref>]. Apigenin is a naturally occurring flavonoid compound (4&#x02032;,5,7-trihydroxyflavone, C<sub>15</sub>H<sub>10</sub>O<sub>5</sub>) found in fruits and vegetables. Apigenin has been demonstrated to possess various pharmacological effects, such as anti-inflammatory [<xref rid="B7-toxics-13-00112" ref-type="bibr">7</xref>], anti-viral [<xref rid="B8-toxics-13-00112" ref-type="bibr">8</xref>,<xref rid="B9-toxics-13-00112" ref-type="bibr">9</xref>], and anti-oxidative effects [<xref rid="B10-toxics-13-00112" ref-type="bibr">10</xref>,<xref rid="B11-toxics-13-00112" ref-type="bibr">11</xref>]. Apigenin has been shown in several studies to have broad anticancer effects through various mechanisms, including inhibiting proliferation, apoptosis induction, autophagy induction, modulating the signaling pathway involved in cancer progression, and angiogenesis suppression [<xref rid="B12-toxics-13-00112" ref-type="bibr">12</xref>,<xref rid="B13-toxics-13-00112" ref-type="bibr">13</xref>,<xref rid="B14-toxics-13-00112" ref-type="bibr">14</xref>,<xref rid="B15-toxics-13-00112" ref-type="bibr">15</xref>,<xref rid="B16-toxics-13-00112" ref-type="bibr">16</xref>,<xref rid="B17-toxics-13-00112" ref-type="bibr">17</xref>,<xref rid="B18-toxics-13-00112" ref-type="bibr">18</xref>,<xref rid="B19-toxics-13-00112" ref-type="bibr">19</xref>,<xref rid="B20-toxics-13-00112" ref-type="bibr">20</xref>]. These effects have been observed in various types of cancers, including colorectal cancer [<xref rid="B12-toxics-13-00112" ref-type="bibr">12</xref>], breast cancer [<xref rid="B13-toxics-13-00112" ref-type="bibr">13</xref>], liver cancer [<xref rid="B14-toxics-13-00112" ref-type="bibr">14</xref>,<xref rid="B15-toxics-13-00112" ref-type="bibr">15</xref>], lung cancer [<xref rid="B16-toxics-13-00112" ref-type="bibr">16</xref>], cervical cancer [<xref rid="B17-toxics-13-00112" ref-type="bibr">17</xref>], ovarian cancer [<xref rid="B18-toxics-13-00112" ref-type="bibr">18</xref>], prostate cancer [<xref rid="B19-toxics-13-00112" ref-type="bibr">19</xref>], and skin cancer [<xref rid="B20-toxics-13-00112" ref-type="bibr">20</xref>]. Accordingly, the biological effects of apigenin on the cell viability, apoptosis, and migration of human CCA cell line KKU-M055 were investigated in the present study. This research aimed to assess the potential of apigenin as a novel therapeutic agent for treating CCA.</p></sec><sec id="sec2-toxics-13-00112"><title>2. Materials and Methods</title><sec id="sec2dot1-toxics-13-00112"><title>2.1. Cell Culture</title><p>All cell lines, including the KKU-M055 cell line, a human intrahepatic CCA (moderately differentiated adenocarcinoma) (CVCL_M258), and an immortalized human cholangiocyte cell line MMNK1 (CVCL_M266), were obtained from the Japanese Collection of Research Bioresources (JCRB, Osaka, Japan). Cell lines were grown in a Dulbecco&#x02019;s Modified Eagle&#x02019;s Medium high-glucose (DMEM-HG) medium supplemented with 1% <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic> penicillin/streptomycin and 10% <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic> fetal bovine serum (FBS) (all from Life Technologies, Paisley, UK). All cells were cultured and maintained in a humidified incubator at 37 &#x000b0;C with 5% CO<sub>2</sub>.</p></sec><sec id="sec2dot2-toxics-13-00112"><title>2.2. Cell Viability Assay</title><p>Cell viability was assessed to evaluate cytotoxicity using the CellTiter 96<sup>&#x000ae;</sup> AQueous One Solution Cell Proliferation Assay (MTS assay), which utilizes 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (Promega, Madison, WI, USA). Briefly, KKU-M055 cells were seeded in 96-well plates at 5 &#x000d7; 10<sup>3</sup> cells/well, then incubated at 37 &#x000b0;C with 5% CO<sub>2</sub> and allowed to form a confluent monolayer for 24 h. The medium was replaced with a fresh medium that included triplicates of apigenin (C<sub>15</sub>H<sub>10</sub>O<sub>5</sub>, Sigma-Aldrich, St. Louis, MO, USA) at varying concentrations (20, 40, 60, 80, 100, and 120 &#x003bc;M), while untreated cells served as the control. The cells were incubated at 37 &#x000b0;C with 5% CO<sub>2</sub>, and after 24 and 48 h, an MTS assay was conducted in each well. The cells were incubated at 37 &#x000b0;C with 5% CO<sub>2</sub> for 1 h. The absorbance of samples was measured at 490 nm using a microplate reader (Thermo Varioskan Flash Multi Detection microplate reader, Thermo Fisher Scientific, Waltham, MA, USA). The cell viability percentage was calculated relative to untreated controls, and the half-maximal inhibitory concentration (IC50) was determined using a linear regression equation based on the viability data.</p></sec><sec id="sec2dot3-toxics-13-00112"><title>2.3. Cell Cycle Distribution Assay</title><p>For cell cycle analysis, KKU-M055 cells were treated with 80 &#x000b5;M apigenin (the IC50 concentration) for 24 h in triplicate, while untreated cells served as the control. A BD Cycletest&#x02122; Plus Reagent Kit was used following the manufacturer&#x02019;s instructions (BD Biosciences, San Jose, CA, USA). Cell cycle distribution was analyzed using a BD FACSAria II flow cytometer 9.0 (BD Biosciences), and data were processed using BD FACSDiva software 8.0.2 (BD Biosciences).</p></sec><sec id="sec2dot4-toxics-13-00112"><title>2.4. Apoptosis Assay</title><p>The induction of apoptosis in KKU-M055 cells by apigenin was evaluated using flow cytometry. In brief, 2.5 &#x000d7; 10<sup>5</sup> cells in a 25 cm<sup>2</sup> culture flask were treated with 80 &#x003bc;M apigenin for 24 h in triplicate, with untreated cells serving as the control. After treatment, the cells were collected and stained using a FITC Annexin V Apoptosis Detection Kit I (BD Biosciences, San Jose, CA, USA) according to the manufacturer&#x02019;s instructions. The stained cells were then analyzed using a BD FACSAria II flow cytometer 9.0 (BD Biosciences), and data were processed using BD FACSDiva software 8.0.2 (BD Biosciences).</p></sec><sec id="sec2dot5-toxics-13-00112"><title>2.5. Apoptotic Cell Staining</title><p>Nuclear morphology was examined to evaluate apoptosis using the fluorescent DNA-binding dye Hoechst 33258 solution (5 &#x003bc;g/mL) (Sigma-Aldrich). In brief, 5 &#x000d7; 10<sup>4</sup> cells in a 24-well plate were treated with 80 &#x003bc;M of apigenin for 24 h in triplicate, while untreated cells served as the control. After incubation, the cells were stained with Hoechst 33258 solution at room temperature for 10 min. The stained cells were then observed under a fluorescence microscope to examine the morphology of apoptotic nuclei.</p><p>To assess mitochondrial function, a mitochondrial transmembrane potential assay was performed using Rhodamine 123 (Rho 123 staining) (Sigma-Aldrich). In brief, Hoechst 33258-stained cells were incubated with Rho 123 (2.5 &#x003bc;g/mL) at room temperature in the dark for 15 min. After the incubation period, the cells were washed with PBS to remove excess dye. The mitochondrial membrane potential was then evaluated by observing under a fluorescence microscope.</p></sec><sec id="sec2dot6-toxics-13-00112"><title>2.6. Caspase Activity Assay</title><p>The activity of caspase-8, -9, and -3/7 was detected using the Caspase-Glo<sup>&#x000ae;</sup> caspase-8, -9, and -3/7 assay kits (Promega, Madison, WI, USA). Briefly, 5 &#x000d7; 10<sup>3</sup> cells in a black wall, clear bottom 96-well plate were treated with 80 &#x003bc;M apigenin in triplicate, with untreated cells serving as the control. After 24 h of treatment, Caspase-Glo reagent was added to each well and incubated at room temperature for 30 min. Luminescence was subsequently measured using a microplate reader (Thermo Varioskan Flash Multi Detection microplate reader, Thermo Fisher Scientific). Data are expressed as the percentage change compared to the untreated control, which was set to 100% activity.</p></sec><sec id="sec2dot7-toxics-13-00112"><title>2.7. Cell Migration Assay</title><p>The effects of apigenin on cell migration were assessed using a Transwell system (Costar Corning, Kennebunk, ME, USA). In brief, cell suspensions with a density of 2 &#x000d7; 10<sup>5</sup> were prepared in a serum-free medium and seeded into the upper chamber of the Transwell in triplicate. The lower chamber was filled with 10% FBS medium, and 80 &#x003bc;M apigenin was added as a chemoattractant in triplicate, with untreated cells serving as the control group. Following incubation, non-migrating cells on the upper side of the filter were carefully removed using a cotton swab. Migrating cells that had adhered to the underside of the filter were fixed with methanol for 10 min and stained with 2.5% crystal violet for 30 min at room temperature. The number of migrating cells was counted in nine randomly selected and non-overlapping fields under a light microscope at 200&#x000d7; magnification.</p></sec><sec id="sec2dot8-toxics-13-00112"><title>2.8. Statistical Analysis</title><p>Data were analyzed using SPSS version 20 software (IBM Corp., Armonk, NY, USA). The data were expressed as the mean &#x000b1; standard deviation (SD). Group comparisons were analyzed using a two-tailed Student&#x02019;s <italic toggle="yes">t</italic>-test with <italic toggle="yes">p</italic> &#x0003c; 0.05 considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec3-toxics-13-00112"><title>3. Results</title><sec id="sec3dot1-toxics-13-00112"><title>3.1. Apigenin Inhibited Cell Proliferation of CCA Cells</title><p>Cell viability in vitro was assessed using an MTS assay to show the inhibitory effects of apigenin on cell proliferation. MMNK1, an immortalized human cholangiocyte cell line, and KKU-M055, a human CCA cell line, were treated with different concentrations of apigenin, ranging from 20 to 120 &#x003bc;M for 24 and 48 h. The results demonstrated that apigenin effectively inhibited the proliferation of KKU-M055 cells in a dose- and time-dependent manner (<xref rid="toxics-13-00112-f001" ref-type="fig">Figure 1</xref>). After 24 and 48 h of treatment, the IC50 values of apigenin for KKU-M055 cells were 78 &#x003bc;M and 61 &#x003bc;M, respectively. These values were approximately 1.7-fold lower than those for MMNK1 cells (132 &#x003bc;M and 100 &#x003bc;M, respectively), suggesting that apigenin is less toxic to immortalized cholangiocyte cells. Based on the MTS results, a concentration of 80 &#x003bc;M apigenin, corresponding to its IC50 value, was selected for further studies.</p></sec><sec id="sec3dot2-toxics-13-00112"><title>3.2. Apigenin Causes Cell Cycle Arrest in CCA Cells</title><p>The reduction in cell viability may result from the induction of cell growth arrest and/or apoptosis. This study aimed to determine the effects of apigenin on cell cycle progression and apoptosis in CCA cells. KKU-M055 cells were treated with 80 &#x000b5;M apigenin for 24 h to evaluate whether apigenin induces cell cycle arrest. Flow cytometric analysis revealed a significant increase in the number of cells in the G2/M phase (from 19.63 &#x000b1; 0.25 to 27.73 &#x000b1; 1.09%). In contrast, a corresponding decrease in the proportion of cells was observed in the G0/G1 phase (from 59.47 &#x000b1; 0.40% to 55.37 &#x000b1; 0.91%) and S phase (from 16.60 &#x000b1; 0.20% to 13.43 &#x000b1; 0.15%) compared to untreated cells (<italic toggle="yes">p</italic> &#x0003c; 0.01), suggesting that apigenin induces a G2/M cell cycle arrest (<xref rid="toxics-13-00112-f002" ref-type="fig">Figure 2</xref>A,B).</p></sec><sec id="sec3dot3-toxics-13-00112"><title>3.3. Promotion of Apoptosis by Apigenin Through Activation of Extrinsic and Intrinsic Pathways in KKU-M055 Cells</title><p>To examine whether apigenin induced apoptotic cell death in KKU-M055 cells, a flow cytometric analysis of phosphatidylserine (PS) externalization was used to detect cell apoptosis. PS, a type of glycerophospholipid, is a major component of the plasma membrane. In living cells, PS is typically restricted to the inner leaflet of the plasma membrane. PS exposure on the outer plasma membrane is a hallmark of apoptosis, a programmed cell death process distinguished by cell shrinkage, chromatin condensation, the fragmentation of nuclear DNA, and preserved plasma membrane integrity [<xref rid="B21-toxics-13-00112" ref-type="bibr">21</xref>]. When cells undergo an early stage of apoptosis, the event that occurs is PS externalization on the cell surface, detected by Annexin V staining. After the progression to the late stages of apoptosis, PI has labeled apoptotic cells due to the membrane integrity of the cells being lost [<xref rid="B22-toxics-13-00112" ref-type="bibr">22</xref>]. <xref rid="toxics-13-00112-f002" ref-type="fig">Figure 2</xref>C,D demonstrate that in the untreated group, 93.53 &#x000b1; 2.41% of cells remained viable, with less than 7% exhibiting apoptosis. In contrast, treatment with an IC50 concentration of apigenin for 24 h resulted in a significant shift, with 75.33 &#x000b1; 7.29% of cells remaining viable, while 24.67 &#x000b1; 7.43% of cells displayed apoptotic characteristics. This suggests that apigenin induced a notable increase in apoptosis in the KKU-M055 cells.</p><p>The growth inhibitory effects of apigenin on cancer cells were mediated through apoptosis, as demonstrated by hallmark features such as nuclear condensation, the formation of apoptotic bodies, and DNA fragmentation. To further confirm these apoptotic characteristics, cells were stained with Hoechst 33258, enabling the visualization of nuclear morphological changes associated with apoptosis under a fluorescence microscope. Apigenin triggered an apoptotic response in KKU-M055 cells compared to untreated controls. As shown in <xref rid="toxics-13-00112-f003" ref-type="fig">Figure 3</xref>A (first column), apigenin-treated KKU-M055 cells exhibited nuclear condensation and fragmentation (white arrow), which are the characteristic features of apoptosis, indicating that apigenin effectively induces apoptosis in CCA cells.</p><p>To determine whether the observed apoptosis is linked to the loss of mitochondrial membrane potential (&#x00394;&#x003a8;m), cells were stained with Rho 123 dye, a marker of the earliest events in the apoptotic cascade. Apigenin treatment resulted in a reduction in Rho 123 fluorescence compared to untreated cells (<xref rid="toxics-13-00112-f003" ref-type="fig">Figure 3</xref>A, middle column), suggesting that apigenin triggered mitochondrial damage-associated apoptosis in KKU-M055 cells.</p></sec><sec id="sec3dot4-toxics-13-00112"><title>3.4. Effects of Apigenin on Caspase Activity in KKU-M055 Cells</title><p>To assess the impact of apigenin on the activities of key caspases (caspase-8, -9, and -3/7) in CCA cells, KKU-M055 cells were treated with an IC50 concentration of apigenin for 24 h, and caspase activities were measured using the Caspase-Glo kits. As shown in <xref rid="toxics-13-00112-f003" ref-type="fig">Figure 3</xref>B, the treatment with apigenin resulted in a significant increase in the activities of caspase-8, -9, and -3/7 compared to the untreated cells, with the differences being statistically significant (<italic toggle="yes">p</italic> &#x0003c; 0.01). These results suggested that apigenin induces apoptosis in CCA cells through both extrinsic and intrinsic apoptotic pathways by enhancing the activity of caspases-8, -9, and -3/7 (<xref rid="toxics-13-00112-f003" ref-type="fig">Figure 3</xref>C).</p></sec><sec id="sec3dot5-toxics-13-00112"><title>3.5. Inhibition of KKU-M055 Cell Migration by Apigenin</title><p>To assess whether apigenin can inhibit the migration of CCA cells, its effect on cell motility was evaluated using a Transwell migration assay. As shown in <xref rid="toxics-13-00112-f004" ref-type="fig">Figure 4</xref>, apigenin treatment significantly reduced the migration of KKU-M055 cells by 38.11 &#x000b1; 13.86% compared to untreated cells. These results suggest that apigenin effectively inhibits the migration of CCA cells.</p></sec></sec><sec sec-type="discussion" id="sec4-toxics-13-00112"><title>4. Discussion</title><p>CCA is a rare and aggressive cancer with a poor prognosis, and its incidence is rising. This highlights the critical need for the development of novel therapeutic compounds to improve outcomes and address the current lack of effective treatment options [<xref rid="B23-toxics-13-00112" ref-type="bibr">23</xref>]. Apigenin, a natural dietary flavonoid, is found in various vegetables, herbs, and fruits. It has been demonstrated to suppress tumor growth by inhibiting cell proliferation [<xref rid="B12-toxics-13-00112" ref-type="bibr">12</xref>,<xref rid="B13-toxics-13-00112" ref-type="bibr">13</xref>,<xref rid="B14-toxics-13-00112" ref-type="bibr">14</xref>,<xref rid="B15-toxics-13-00112" ref-type="bibr">15</xref>,<xref rid="B16-toxics-13-00112" ref-type="bibr">16</xref>,<xref rid="B17-toxics-13-00112" ref-type="bibr">17</xref>,<xref rid="B18-toxics-13-00112" ref-type="bibr">18</xref>,<xref rid="B19-toxics-13-00112" ref-type="bibr">19</xref>,<xref rid="B20-toxics-13-00112" ref-type="bibr">20</xref>]. In this study, we demonstrated the chemotherapeutic potential of apigenin against CCA in vitro. The human CCA cell line KKU-M055 derived from a human intrahepatic CCA was selected as a model for our investigation. Our findings revealed that apigenin inhibited the proliferation of KKU-M055 cells while exhibiting low toxicity in immortalized human cholangiocyte cell line MMNK1 cells. Additionally, we tested cell viability on another CCA cell line (KKU-M213A) (CVCL_M261, JCRB), and the results were similar to those observed with KKU-M055, indicating that apigenin has a comparable effect on KKU-M213A (<xref rid="app1-toxics-13-00112" ref-type="app">Figure S1</xref>). These findings suggest that apigenin possesses chemotherapeutic potential in the treatment of CCA. Consistent with our findings, previous studies found that apigenin suppresses cell proliferation and causes apoptosis in various cancer cell types [<xref rid="B12-toxics-13-00112" ref-type="bibr">12</xref>,<xref rid="B13-toxics-13-00112" ref-type="bibr">13</xref>,<xref rid="B14-toxics-13-00112" ref-type="bibr">14</xref>,<xref rid="B15-toxics-13-00112" ref-type="bibr">15</xref>,<xref rid="B16-toxics-13-00112" ref-type="bibr">16</xref>,<xref rid="B17-toxics-13-00112" ref-type="bibr">17</xref>,<xref rid="B18-toxics-13-00112" ref-type="bibr">18</xref>,<xref rid="B19-toxics-13-00112" ref-type="bibr">19</xref>,<xref rid="B20-toxics-13-00112" ref-type="bibr">20</xref>], while apigenin displays low cytotoxicity in normal cells [<xref rid="B24-toxics-13-00112" ref-type="bibr">24</xref>,<xref rid="B25-toxics-13-00112" ref-type="bibr">25</xref>].</p><p>Cell cycle dysregulation is a hallmark of tumorigenesis, caused by the breakdown of multiple tightly regulated checkpoints. The G2/M checkpoint prevents cells from entering mitosis when DNA damage is present, allowing for time for repair and preventing the proliferation of damaged cells [<xref rid="B26-toxics-13-00112" ref-type="bibr">26</xref>]. Apoptotic pathways are triggered to eliminate affected cells if the damage is irreparable [<xref rid="B27-toxics-13-00112" ref-type="bibr">27</xref>]. Our findings reveal that apigenin suppressed the growth of human CCA cells by inducing the G2/M-phase arrest of the cell cycle. Several studies have demonstrated that apigenin inhibits cancer cell proliferation by modulating the cell cycle and inducing a G2/M phase in various cancer cell types. These include hepatocellular carcinoma [<xref rid="B14-toxics-13-00112" ref-type="bibr">14</xref>,<xref rid="B15-toxics-13-00112" ref-type="bibr">15</xref>], human colorectal carcinoma HCT116 cells [<xref rid="B28-toxics-13-00112" ref-type="bibr">28</xref>], human breast cancer cell line MDA-MB-231 cells [<xref rid="B29-toxics-13-00112" ref-type="bibr">29</xref>], renal cell carcinoma ACHN cells [<xref rid="B30-toxics-13-00112" ref-type="bibr">30</xref>], adenoid cystic carcinoma ACC-2 cells [<xref rid="B31-toxics-13-00112" ref-type="bibr">31</xref>], and human papillary thyroid carcinoma BCPAP cells [<xref rid="B32-toxics-13-00112" ref-type="bibr">32</xref>]. Furthermore, apigenin has been reported to induce cell cycle arrest at the G0/G1 or S phase checkpoints in LNCaP human prostate cancer cells [<xref rid="B24-toxics-13-00112" ref-type="bibr">24</xref>]. In the SCC-25 oral squamous cell carcinoma cell line, apigenin treatment was found to cause cell cycle arrest at both the G0/G1 and G2/M phase checkpoints [<xref rid="B33-toxics-13-00112" ref-type="bibr">33</xref>]. These findings suggest that the effects of apigenin on cell cycle progression may vary depending on the specific characteristics of the cell line.</p><p>Apoptosis is a form of programmed cell death (PCD) that plays a crucial role in physiological development and is essential for maintaining tissue homeostasis [<xref rid="B34-toxics-13-00112" ref-type="bibr">34</xref>]. The activation of caspases is the hallmark of the investigation of apoptosis pathways. Caspase-8 activation is associated with the extrinsic pathway, while caspase-9 activation mediates the intrinsic pathway. In the extrinsic pathway, cleaved caspase-8 activates caspase-3, thereby initiating apoptosis. In the intrinsic pathway, caspase-9 triggers the release of cytochrome c from mitochondria in response to various agents or insults, which subsequently activates caspase-3, a common downstream effector in both pathways [<xref rid="B35-toxics-13-00112" ref-type="bibr">35</xref>]. In our study, we demonstrated that apigenin treatment significantly increased the apoptosis rates of KKU-M055 cells compared to the control group. Furthermore, apigenin treatment enhanced the expression of caspase-8, -9, and -3/7, which are key markers of apoptotic activity. Our findings are consistent with previous reports, which have demonstrated that apigenin induced cancer cell apoptosis through both extrinsic and intrinsic pathways [<xref rid="B36-toxics-13-00112" ref-type="bibr">36</xref>,<xref rid="B37-toxics-13-00112" ref-type="bibr">37</xref>]. Zhao et al. found that apigenin promotes the apoptosis pathway by activating cleaved caspase-3 and cleaved PARP proteins [<xref rid="B20-toxics-13-00112" ref-type="bibr">20</xref>]. Additionally, Seo et al. observed that apigenin induces apoptosis through the extrinsic pathway by activating p53 and suppressing STAT3 and NF-&#x003ba;B signaling in human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer cells [<xref rid="B38-toxics-13-00112" ref-type="bibr">38</xref>]. Furthermore, we observed that apigenin induced DNA fragmentation and the loss of mitochondrial membrane potential (&#x00394;&#x003a8;m) in KKU-M055 cells. These observations are in line with previous research demonstrating that apigenin can induce similar effects in other cancer cell types, including human breast cancer MDA-MB-453 cells [<xref rid="B39-toxics-13-00112" ref-type="bibr">39</xref>] and human bladder cancer T-24 cells [<xref rid="B40-toxics-13-00112" ref-type="bibr">40</xref>]. This consistency suggests that apigenin has an impact on DNA integrity, and mitochondrial function may be a common mechanism across different cancer cell lines.</p><p>Cancer cell migration and invasion play an important role in tumor metastasis, which is an adverse prognostic factor contributing to cancer-related mortality [<xref rid="B41-toxics-13-00112" ref-type="bibr">41</xref>]. We found that apigenin significantly inhibited KKU-M055 cell migration. Consistent with other reports, apigenin has been demonstrated to be an effective agent for inhibiting cell migration in CD44+ prostate cancer cells [<xref rid="B42-toxics-13-00112" ref-type="bibr">42</xref>] and colorectal cancer cells (DLD1 and SW480) [<xref rid="B43-toxics-13-00112" ref-type="bibr">43</xref>]. Moreover, Qin et al. found that apigenin inhibited the invasion and migration of human hepatocellular carcinoma cells (Bel-7402 and PLC) by suppressing the NF-&#x003ba;B/Snail pathway and reversing the upregulation of epithelial&#x02013;mesenchymal transition (EMT) marker levels [<xref rid="B44-toxics-13-00112" ref-type="bibr">44</xref>].</p></sec><sec sec-type="conclusions" id="sec5-toxics-13-00112"><title>5. Conclusions</title><p>In conclusion, our study demonstrates that apigenin significantly suppressed KKU-M055 CCA cell proliferation in a dose- and time-dependent manner by inducing the G2/M-phase arrest of the cell cycle. Additionally, apigenin was shown to activate both the extrinsic and intrinsic pathways of apoptosis via the activation of caspase-8, -9, and -3/7. Moreover, apigenin also inhibits cancer cell migration. All these results indicate that apigenin can be used as a chemopreventive agent in CCA due to its characteristics of safety, low toxicity, and high efficiency. To the best of our knowledge, this is the first report showing the anticancer and anti-migration effects of apigenin in CCA cancer in vitro. However, it is important to note that the analysis was conducted using a single cancer cell line. Future studies involving multiple types of CCA cell lines to investigate the mechanisms behind apigenin-induced cell inhibition, as well as evaluating its effects on in vivo models, may provide a more comprehensive understanding of its therapeutic potential and outcomes specific to CCA.</p></sec></body><back><ack><title>Acknowledgments</title><p>We are grateful to Thammasat University Research Unit in Biomedical Science and Advanced Science and Technology, Thammasat University, for their technological equipment.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-toxics-13-00112"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at <uri xlink:href="https://www.mdpi.com/article/10.3390/toxics13020112/s1">https://www.mdpi.com/article/10.3390/toxics13020112/s1</uri>, Figure S1: Cytotoxicity effect of apigenin on MMNK1 immortalized human cholangiocyte, KKU-M055, and KKU-M213A human cholangiocarcinoma cells.</p><supplementary-material id="toxics-13-00112-s001" position="float" content-type="local-data"><media xlink:href="toxics-13-00112-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, N.N.; methodology, N.N. and M.K.; software, N.N. and M.K.; validation, N.N. and M.K.; formal analysis, N.N.; investigation, N.N.; resources, T.L.; data curation, N.N. and M.K.; writing&#x02014;original draft preparation, M.K.; writing&#x02014;review and editing, N.N.; visualization, T.L.; supervision, T.L.; project administration, N.N.; funding acquisition, N.N. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in this study are included in the article/<xref rid="app1-toxics-13-00112" ref-type="app">Supplementary Material</xref>. Further inquiries can be directed to the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-toxics-13-00112"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chamadol</surname><given-names>N.</given-names></name>
<name><surname>Laopaiboon</surname><given-names>V.</given-names></name>
<name><surname>Jareanrat</surname><given-names>A.</given-names></name>
<name><surname>Thanasukarn</surname><given-names>V.</given-names></name>
<name><surname>Srisuk</surname><given-names>T.</given-names></name>
<name><surname>Luvira</surname><given-names>V.</given-names></name>
<name><surname>Sarkhampee</surname><given-names>P.</given-names></name>
<name><surname>Ungpinitpong</surname><given-names>W.</given-names></name>
<name><surname>Khamvijite</surname><given-names>P.</given-names></name>
<name><surname>Chumnanua</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Improvement of survival outcomes of cholangiocarcinoma by ultrasonography surveillance: Multicenter retrospective cohorts</article-title><source>Heliyon</source><year>2024</year><volume>10</volume><fpage>e38191</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e38191</pub-id><pub-id pub-id-type="pmid">39381227</pub-id>
</element-citation></ref><ref id="B2-toxics-13-00112"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khuntikeo</surname><given-names>N.</given-names></name>
<name><surname>Koonmee</surname><given-names>S.</given-names></name>
<name><surname>Sa-Ngiamwibool</surname><given-names>P.</given-names></name>
<name><surname>Chamadol</surname><given-names>N.</given-names></name>
<name><surname>Laopaiboon</surname><given-names>V.</given-names></name>
<name><surname>Titapun</surname><given-names>A.</given-names></name>
<name><surname>Yongvanit</surname><given-names>P.</given-names></name>
<name><surname>Loilome</surname><given-names>W.</given-names></name>
<name><surname>Namwat</surname><given-names>N.</given-names></name>
<name><surname>Andrews</surname><given-names>R.H.</given-names></name>
<etal/>
</person-group><article-title>A comparison of the proportion of early stage cholangiocarcinoma found in an ultrasound-screening program compared to walk-in patients</article-title><source>HPB</source><year>2020</year><volume>22</volume><fpage>874</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1016/j.hpb.2019.10.010</pub-id><pub-id pub-id-type="pmid">31662222</pub-id>
</element-citation></ref><ref id="B3-toxics-13-00112"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Christina</surname><given-names>V.</given-names></name>
<name><surname>Carl</surname><given-names>J.</given-names></name>
<name><surname>Annika</surname><given-names>B.</given-names></name>
</person-group><article-title>Treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis: A comprehensive review</article-title><source>eGastroenterology</source><year>2024</year><volume>2</volume><fpage>e100045</fpage><pub-id pub-id-type="pmid">39944751</pub-id>
</element-citation></ref><ref id="B4-toxics-13-00112"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jung</surname><given-names>K.</given-names></name>
<name><surname>Park</surname><given-names>J.</given-names></name>
<name><surname>Jung</surname><given-names>J.H.</given-names></name>
<name><surname>Lee</surname><given-names>J.-C.</given-names></name>
<name><surname>Kim</surname><given-names>J.</given-names></name>
<name><surname>Hwang</surname><given-names>J.-H.</given-names></name>
</person-group><article-title>Real-World Outcomes of Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy Regimen for Advanced Biliary Tract Cancer: A Propensity Score-Matched Analysis</article-title><source>Gut Liver</source><year>2022</year><volume>16</volume><fpage>798</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.5009/gnl210346</pub-id><pub-id pub-id-type="pmid">35000934</pub-id>
</element-citation></ref><ref id="B5-toxics-13-00112"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>Q.</given-names></name>
<name><surname>Zhang</surname><given-names>B.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
</person-group><article-title>Overcome Drug Resistance in Cholangiocarcinoma: New Insight Into Mechanisms and Refining the Preclinical Experiment Models</article-title><source>Front. Oncol.</source><year>2022</year><volume>12</volume><elocation-id>850732</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2022.850732</pub-id><pub-id pub-id-type="pmid">35372014</pub-id>
</element-citation></ref><ref id="B6-toxics-13-00112"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Olayiwola</surname><given-names>Y.</given-names></name>
<name><surname>Gollahon</surname><given-names>L.</given-names></name>
</person-group><article-title>Natural Compounds and Breast Cancer: Chemo-Preventive and Therapeutic Capabilities of Chlorogenic Acid and Cinnamaldehyde</article-title><source>Pharmaceuticals</source><year>2024</year><volume>17</volume><elocation-id>361</elocation-id><pub-id pub-id-type="doi">10.3390/ph17030361</pub-id><pub-id pub-id-type="pmid">38543147</pub-id>
</element-citation></ref><ref id="B7-toxics-13-00112"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lim</surname><given-names>R.</given-names></name>
<name><surname>Barker</surname><given-names>G.</given-names></name>
<name><surname>Wall</surname><given-names>C.A.</given-names></name>
<name><surname>Lappas</surname><given-names>M.</given-names></name>
</person-group><article-title>Dietary phytophenols curcumin, naringenin and apigenin reduce infection-induced inflammatory and contractile pathways in human placenta, foetal membranes and myometrium</article-title><source>Mol. Hum. Reprod.</source><year>2013</year><volume>19</volume><fpage>451</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1093/molehr/gat015</pub-id><pub-id pub-id-type="pmid">23475986</pub-id>
</element-citation></ref><ref id="B8-toxics-13-00112"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qian</surname><given-names>S.</given-names></name>
<name><surname>Fan</surname><given-names>W.</given-names></name>
<name><surname>Qian</surname><given-names>P.</given-names></name>
<name><surname>Zhang</surname><given-names>D.</given-names></name>
<name><surname>Wei</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
</person-group><article-title>Apigenin Restricts FMDV Infection and Inhibits Viral IRES Driven Translational Activity</article-title><source>Viruses</source><year>2015</year><volume>7</volume><fpage>1613</fpage><lpage>1626</lpage><pub-id pub-id-type="doi">10.3390/v7041613</pub-id><pub-id pub-id-type="pmid">25835532</pub-id>
</element-citation></ref><ref id="B9-toxics-13-00112"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
</person-group><article-title>Preparation, in-vitro release and antioxidant potential of formulation of apigenin with hydroxypropyl-&#x003b2;-cyclodextrin modified microemulsion</article-title><source>J. Incl. Phenom. Macrocycl. Chem.</source><year>2016</year><volume>86</volume><fpage>93</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1007/s10847-016-0644-x</pub-id></element-citation></ref><ref id="B10-toxics-13-00112"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>B.-K.</given-names></name>
<name><surname>Cho</surname><given-names>A.-R.</given-names></name>
<name><surname>Park</surname><given-names>D.-J.</given-names></name>
</person-group><article-title>Enhancing oral bioavailability using preparations of apigenin-loaded W/O/W emulsions: In vitro and in vivo evaluations</article-title><source>Food Chem.</source><year>2016</year><volume>206</volume><fpage>85</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.foodchem.2016.03.052</pub-id><pub-id pub-id-type="pmid">27041302</pub-id>
</element-citation></ref><ref id="B11-toxics-13-00112"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Telange</surname><given-names>D.R.</given-names></name>
<name><surname>Patil</surname><given-names>A.T.</given-names></name>
<name><surname>Pethe</surname><given-names>A.M.</given-names></name>
<name><surname>Fegade</surname><given-names>H.</given-names></name>
<name><surname>Anand</surname><given-names>S.</given-names></name>
<name><surname>Dave</surname><given-names>V.S.</given-names></name>
</person-group><article-title>Formulation and characterization of an apigenin-phospholipid phytosome (APLC) for improved solubility, in vivo bioavailability, and antioxidant potential</article-title><source>Eur. J. Pharm. Sci.</source><year>2017</year><volume>108</volume><fpage>36</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2016.12.009</pub-id><pub-id pub-id-type="pmid">27939619</pub-id>
</element-citation></ref><ref id="B12-toxics-13-00112"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Song</surname><given-names>Y.U.</given-names></name>
<name><surname>Yao</surname><given-names>J.</given-names></name>
<name><surname>Huang</surname><given-names>K.</given-names></name>
<name><surname>Zhu</surname><given-names>X.</given-names></name>
</person-group><article-title>Apigenin suppresses colorectal cancer cell proliferation, migration and invasion via inhibition of the Wnt/beta-catenin signaling pathway</article-title><source>Oncol. Lett.</source><year>2016</year><volume>11</volume><fpage>3075</fpage><lpage>3080</lpage><pub-id pub-id-type="doi">10.3892/ol.2016.4331</pub-id><pub-id pub-id-type="pmid">27123066</pub-id>
</element-citation></ref><ref id="B13-toxics-13-00112"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scherbakov</surname><given-names>A.M.</given-names></name>
<name><surname>Andreeva</surname><given-names>O.E.</given-names></name>
</person-group><article-title>Apigenin Inhibits Growth of Breast Cancer Cells: The Role of ERalpha and HER2/neu</article-title><source>Acta Naturae</source><year>2015</year><volume>7</volume><fpage>133</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.32607/20758251-2015-7-3-133-139</pub-id><pub-id pub-id-type="pmid">26483970</pub-id>
</element-citation></ref><ref id="B14-toxics-13-00112"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khan</surname><given-names>T.H.</given-names></name>
<name><surname>Sultana</surname><given-names>S.</given-names></name>
</person-group><article-title>Apigenin induces apoptosis in Hep G2 cells: Possible role of TNF-&#x003b1; and IFN-&#x003b3;</article-title><source>Toxicology</source><year>2006</year><volume>217</volume><fpage>206</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1016/j.tox.2005.09.019</pub-id><pub-id pub-id-type="pmid">16289292</pub-id>
</element-citation></ref><ref id="B15-toxics-13-00112"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>S.M.</given-names></name>
<name><surname>Yang</surname><given-names>P.W.</given-names></name>
<name><surname>Feng</surname><given-names>X.J.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.W.</given-names></name>
<name><surname>Qiu</surname><given-names>F.J.</given-names></name>
<name><surname>Hu</surname><given-names>X.D.</given-names></name>
<name><surname>Zhang</surname><given-names>S.H.</given-names></name>
</person-group><article-title>Apigenin Inhibits the Growth of Hepatocellular Carcinoma Cells by Affecting the Expression of microRNA Transcriptome</article-title><source>Front. Oncol.</source><year>2021</year><volume>11</volume><elocation-id>657665</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2021.657665</pub-id><pub-id pub-id-type="pmid">33959508</pub-id>
</element-citation></ref><ref id="B16-toxics-13-00112"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Zha</surname><given-names>D.</given-names></name>
<name><surname>Cai</surname><given-names>F.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>He</surname><given-names>Y.</given-names></name>
<name><surname>Huang</surname><given-names>Q.</given-names></name>
<name><surname>Zhuang</surname><given-names>H.</given-names></name>
<name><surname>Hua</surname><given-names>Z.C.</given-names></name>
</person-group><article-title>Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><elocation-id>35468</elocation-id><pub-id pub-id-type="doi">10.1038/srep35468</pub-id><pub-id pub-id-type="pmid">27752089</pub-id>
</element-citation></ref><ref id="B17-toxics-13-00112"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Fa</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>B.</given-names></name>
</person-group><article-title>Apigenin exerts anticancer effects on human cervical cancer cells via induction of apoptosis and regulation of Raf/MEK/ERK signalling pathway</article-title><source>Trop. J. Pharm. Res.</source><year>2018</year><volume>17</volume><fpage>1615</fpage><lpage>1619</lpage><pub-id pub-id-type="doi">10.4314/tjpr.v17i8.21</pub-id></element-citation></ref><ref id="B18-toxics-13-00112"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>X.-W.</given-names></name>
<name><surname>Meng</surname><given-names>D.</given-names></name>
<name><surname>Fang</surname><given-names>J.</given-names></name>
</person-group><article-title>Apigenin inhibited migration and invasion of human ovarian cancer A2780 cells through focal adhesion kinase</article-title><source>Carcinogenesis</source><year>2008</year><volume>29</volume><fpage>2369</fpage><lpage>2376</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgn244</pub-id><pub-id pub-id-type="pmid">18974065</pub-id>
</element-citation></ref><ref id="B19-toxics-13-00112"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shukla</surname><given-names>S.</given-names></name>
<name><surname>Bhaskaran</surname><given-names>N.</given-names></name>
<name><surname>Babcook</surname><given-names>M.A.</given-names></name>
<name><surname>Fu</surname><given-names>P.</given-names></name>
<name><surname>Maclennan</surname><given-names>G.T.</given-names></name>
<name><surname>Gupta</surname><given-names>S.</given-names></name>
</person-group><article-title>Apigenin inhibits prostate cancer progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway</article-title><source>Carcinogenesis</source><year>2014</year><volume>35</volume><fpage>452</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgt316</pub-id><pub-id pub-id-type="pmid">24067903</pub-id>
</element-citation></ref><ref id="B20-toxics-13-00112"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>G.</given-names></name>
<name><surname>Han</surname><given-names>X.</given-names></name>
<name><surname>Cheng</surname><given-names>W.</given-names></name>
<name><surname>Ni</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Lin</surname><given-names>J.</given-names></name>
<name><surname>Song</surname><given-names>Z.</given-names></name>
</person-group><article-title>Apigenin inhibits proliferation and invasion, and induces apoptosis and cell cycle arrest in human melanoma cells</article-title><source>Oncol. Rep.</source><year>2017</year><volume>37</volume><fpage>2277</fpage><lpage>2285</lpage><pub-id pub-id-type="doi">10.3892/or.2017.5450</pub-id><pub-id pub-id-type="pmid">28260058</pub-id>
</element-citation></ref><ref id="B21-toxics-13-00112"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Calianese</surname><given-names>D.C.</given-names></name>
<name><surname>Birge</surname><given-names>R.B.</given-names></name>
</person-group><article-title>Biology of phosphatidylserine (PS): Basic physiology and implications in immunology, infectious disease, and cancer</article-title><source>Cell Commun. Signal</source><year>2020</year><volume>18</volume><fpage>41</fpage><pub-id pub-id-type="doi">10.1186/s12964-020-00543-8</pub-id><pub-id pub-id-type="pmid">32160904</pub-id>
</element-citation></ref><ref id="B22-toxics-13-00112"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Costigan</surname><given-names>A.</given-names></name>
<name><surname>Hollville</surname><given-names>E.</given-names></name>
<name><surname>Martin</surname><given-names>S.J.</given-names></name>
</person-group><article-title>Discriminating Between Apoptosis, Necrosis, Necroptosis, and Ferroptosis by Microscopy and Flow Cytometry</article-title><source>Curr. Protoc.</source><year>2023</year><volume>3</volume><fpage>e951</fpage><pub-id pub-id-type="doi">10.1002/cpz1.951</pub-id><pub-id pub-id-type="pmid">38112058</pub-id>
</element-citation></ref><ref id="B23-toxics-13-00112"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cigliano</surname><given-names>A.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Calvisi</surname><given-names>D.F.</given-names></name>
</person-group><article-title>Current challenges to underpinning the genetic basis for cholangiocarcinoma</article-title><source>Expert Rev. Gastroenterol. Hepatol.</source><year>2021</year><volume>15</volume><fpage>511</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1080/17474124.2021.1915128</pub-id><pub-id pub-id-type="pmid">33888034</pub-id>
</element-citation></ref><ref id="B24-toxics-13-00112"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>S.</given-names></name>
<name><surname>Afaq</surname><given-names>F.</given-names></name>
<name><surname>Mukhtar</surname><given-names>H.</given-names></name>
</person-group><article-title>Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2001</year><volume>287</volume><fpage>914</fpage><lpage>920</lpage><pub-id pub-id-type="doi">10.1006/bbrc.2001.5672</pub-id><pub-id pub-id-type="pmid">11573952</pub-id>
</element-citation></ref><ref id="B25-toxics-13-00112"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Way</surname><given-names>T.-D.</given-names></name>
<name><surname>Kao</surname><given-names>M.-C.</given-names></name>
<name><surname>Lin</surname><given-names>J.-K.</given-names></name>
</person-group><article-title>Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>4479</fpage><lpage>4489</lpage><pub-id pub-id-type="doi">10.1074/jbc.M305529200</pub-id><pub-id pub-id-type="pmid">14602723</pub-id>
</element-citation></ref><ref id="B26-toxics-13-00112"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Petsalaki</surname><given-names>E.</given-names></name>
<name><surname>Zachos</surname><given-names>G.</given-names></name>
</person-group><article-title>DNA damage response proteins regulating mitotic cell division: Double agents preserving genome stability</article-title><source>FEBS J.</source><year>2020</year><volume>287</volume><fpage>1700</fpage><lpage>1721</lpage><pub-id pub-id-type="doi">10.1111/febs.15240</pub-id><pub-id pub-id-type="pmid">32027459</pub-id>
</element-citation></ref><ref id="B27-toxics-13-00112"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumari</surname><given-names>R.</given-names></name>
<name><surname>Jat</surname><given-names>P.</given-names></name>
</person-group><article-title>Mechanisms of cellular senescence: Cell cycle arrest and senescence associated secretory phenotype</article-title><source>Front. Cell. Dev. Biol.</source><year>2021</year><volume>9</volume><elocation-id>645593</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2021.645593</pub-id><pub-id pub-id-type="pmid">33855023</pub-id>
</element-citation></ref><ref id="B28-toxics-13-00112"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>Y.</given-names></name>
<name><surname>Sung</surname><given-names>B.</given-names></name>
<name><surname>Kang</surname><given-names>Y.J.</given-names></name>
<name><surname>Kim</surname><given-names>D.H.</given-names></name>
<name><surname>Jang</surname><given-names>J.-Y.</given-names></name>
<name><surname>Hwang</surname><given-names>S.Y.</given-names></name>
<name><surname>Kim</surname><given-names>M.</given-names></name>
<name><surname>Lim</surname><given-names>H.S.</given-names></name>
<name><surname>Yoon</surname><given-names>J.-H.</given-names></name>
<name><surname>Chung</surname><given-names>H.Y.</given-names></name>
<etal/>
</person-group><article-title>Apigenin-induced apoptosis is enhanced by inhibition of autophagy formation in HCT116 human colon cancer cells</article-title><source>Int. J. Oncol.</source><year>2014</year><volume>44</volume><fpage>1599</fpage><lpage>1606</lpage><pub-id pub-id-type="doi">10.3892/ijo.2014.2339</pub-id><pub-id pub-id-type="pmid">24626522</pub-id>
</element-citation></ref><ref id="B29-toxics-13-00112"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tseng</surname><given-names>T.-H.</given-names></name>
<name><surname>Chien</surname><given-names>M.-H.</given-names></name>
<name><surname>Lin</surname><given-names>W.-L.</given-names></name>
<name><surname>Wen</surname><given-names>Y.-C.</given-names></name>
<name><surname>Chow</surname><given-names>J.-M.</given-names></name>
<name><surname>Chen</surname><given-names>C.-K.</given-names></name>
<name><surname>Kuo</surname><given-names>T.-C.</given-names></name>
<name><surname>Lee</surname><given-names>W.-J.</given-names></name>
</person-group><article-title>Inhibition of MDA-MB-231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation-mediated p21WAF1/CIP1 expression</article-title><source>Env. Toxicol.</source><year>2017</year><volume>32</volume><fpage>434</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1002/tox.22247</pub-id><pub-id pub-id-type="pmid">26872304</pub-id>
</element-citation></ref><ref id="B30-toxics-13-00112"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meng</surname><given-names>S.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>J.F.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Liang</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>S.Q.</given-names></name>
<name><surname>Xu</surname><given-names>X.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>B.</given-names></name>
<name><surname>Zheng</surname><given-names>X.Y.</given-names></name>
<etal/>
</person-group><article-title>Apigenin inhibits renal cell carcinoma cell proliferation</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>19834</fpage><lpage>19842</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.15771</pub-id><pub-id pub-id-type="pmid">28423637</pub-id>
</element-citation></ref><ref id="B31-toxics-13-00112"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fang</surname><given-names>J.</given-names></name>
<name><surname>Bao</surname><given-names>Y.Y.</given-names></name>
<name><surname>Zhou</surname><given-names>S.H.</given-names></name>
<name><surname>Fan</surname><given-names>J.</given-names></name>
</person-group><article-title>Apigenin inhibits the proliferation of adenoid cystic carcinoma via suppression of glucose transporter-1</article-title><source>Mol. Med. Rep.</source><year>2015</year><volume>12</volume><fpage>6461</fpage><lpage>6466</lpage><pub-id pub-id-type="doi">10.3892/mmr.2015.4233</pub-id><pub-id pub-id-type="pmid">26300442</pub-id>
</element-citation></ref><ref id="B32-toxics-13-00112"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Cheng</surname><given-names>X.</given-names></name>
<name><surname>Gao</surname><given-names>Y.</given-names></name>
<name><surname>Zheng</surname><given-names>J.</given-names></name>
<name><surname>Xu</surname><given-names>Q.</given-names></name>
<name><surname>Sun</surname><given-names>Y.</given-names></name>
<name><surname>Guan</surname><given-names>H.</given-names></name>
<name><surname>Yu</surname><given-names>H.</given-names></name>
<name><surname>Sun</surname><given-names>Z.</given-names></name>
</person-group><article-title>Apigenin induces autophagic cell death in human papillary thyroid carcinoma BCPAP cells</article-title><source>Food Funct.</source><year>2015</year><volume>6</volume><fpage>3464</fpage><lpage>3472</lpage><pub-id pub-id-type="doi">10.1039/C5FO00671F</pub-id><pub-id pub-id-type="pmid">26292725</pub-id>
</element-citation></ref><ref id="B33-toxics-13-00112"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maggioni</surname><given-names>D.</given-names></name>
<name><surname>Garavello</surname><given-names>W.</given-names></name>
<name><surname>Rigolio</surname><given-names>R.</given-names></name>
<name><surname>Pignataro</surname><given-names>L.</given-names></name>
<name><surname>Gaini</surname><given-names>R.</given-names></name>
<name><surname>Nicolini</surname><given-names>G.</given-names></name>
</person-group><article-title>Apigenin impairs oral squamous cell carcinoma growth in vitro inducing cell cycle arrest and apoptosis</article-title><source>Int. J. Oncol.</source><year>2013</year><volume>43</volume><fpage>1675</fpage><lpage>1682</lpage><pub-id pub-id-type="doi">10.3892/ijo.2013.2072</pub-id><pub-id pub-id-type="pmid">23969487</pub-id>
</element-citation></ref><ref id="B34-toxics-13-00112"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saddam</surname><given-names>M.</given-names></name>
<name><surname>Paul</surname><given-names>S.K.</given-names></name>
<name><surname>Habib</surname><given-names>M.A.</given-names></name>
<name><surname>Fahim</surname><given-names>A.</given-names></name>
<name><surname>Mimi</surname><given-names>A.</given-names></name>
<name><surname>Islam</surname><given-names>S.</given-names></name>
<name><surname>Paul</surname><given-names>B.</given-names></name>
<name><surname>Helal</surname><given-names>M.U.</given-names></name>
</person-group><article-title>Emerging biomarkers and potential therapeutics of the BCL-2 protein family: The apoptotic and anti-apoptotic context</article-title><source>Egypt. J. Med. Hum. Genet.</source><year>2024</year><volume>25</volume><fpage>12</fpage><pub-id pub-id-type="doi">10.1186/s43042-024-00485-7</pub-id></element-citation></ref><ref id="B35-toxics-13-00112"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>G.</given-names></name>
</person-group><article-title>Death and survival from executioner caspase activation</article-title><source>Semin. Cell Dev. Biol.</source><year>2024</year><volume>156</volume><fpage>66</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2023.07.005</pub-id><pub-id pub-id-type="pmid">37468421</pub-id>
</element-citation></ref><ref id="B36-toxics-13-00112"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>B.</given-names></name>
<name><surname>Zhao</surname><given-names>X.-H.</given-names></name>
</person-group><article-title>Apigenin induces both intrinsic and extrinsic pathways of apoptosis in human colon carcinoma HCT-116 cells</article-title><source>Oncol. Rep.</source><year>2017</year><volume>37</volume><fpage>1132</fpage><lpage>1140</lpage><pub-id pub-id-type="doi">10.3892/or.2016.5303</pub-id><pub-id pub-id-type="pmid">27959417</pub-id>
</element-citation></ref><ref id="B37-toxics-13-00112"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karmakar</surname><given-names>S.</given-names></name>
<name><surname>Davis</surname><given-names>K.A.</given-names></name>
<name><surname>Choudhury</surname><given-names>S.R.</given-names></name>
<name><surname>Deeconda</surname><given-names>A.</given-names></name>
<name><surname>Banik</surname><given-names>N.L.</given-names></name>
<name><surname>Ray</surname><given-names>S.K.</given-names></name>
</person-group><article-title>Bcl-2 inhibitor and apigenin worked synergistically in human malignant neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathways</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2009</year><volume>388</volume><fpage>705</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2009.08.071</pub-id><pub-id pub-id-type="pmid">19695221</pub-id>
</element-citation></ref><ref id="B38-toxics-13-00112"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Seo</surname><given-names>H.S.</given-names></name>
<name><surname>Choi</surname><given-names>H.S.</given-names></name>
<name><surname>Kim</surname><given-names>S.R.</given-names></name>
<name><surname>Choi</surname><given-names>Y.K.</given-names></name>
<name><surname>Woo</surname><given-names>S.M.</given-names></name>
<name><surname>Shin</surname><given-names>I.</given-names></name>
<name><surname>Woo</surname><given-names>J.K.</given-names></name>
<name><surname>Park</surname><given-names>S.Y.</given-names></name>
<name><surname>Shin</surname><given-names>Y.C.</given-names></name>
<name><surname>Ko</surname><given-names>S.G.</given-names></name>
</person-group><article-title>Apigenin induces apoptosis via extrinsic pathway, inducing p53 and inhibiting STAT3 and NF&#x003ba;B signaling in HER2-overexpressing breast cancer cells</article-title><source>Mol. Cell. Biochem.</source><year>2012</year><volume>366</volume><fpage>319</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1007/s11010-012-1310-2</pub-id><pub-id pub-id-type="pmid">22527937</pub-id>
</element-citation></ref><ref id="B39-toxics-13-00112"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Choi</surname><given-names>E.J.</given-names></name>
<name><surname>Kim</surname><given-names>G.-H.</given-names></name>
</person-group><article-title>Apigenin Induces Apoptosis through a Mitochondria/Caspase-Pathway in Human Breast Cancer MDA-MB-453 Cells</article-title><source>J. Clin. Biochem. Nutr.</source><year>2009</year><volume>44</volume><fpage>260</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.3164/jcbn.08-230</pub-id><pub-id pub-id-type="pmid">19430615</pub-id>
</element-citation></ref><ref id="B40-toxics-13-00112"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shi</surname><given-names>M.D.</given-names></name>
<name><surname>Shiao</surname><given-names>C.K.</given-names></name>
<name><surname>Lee</surname><given-names>Y.C.</given-names></name>
<name><surname>Shih</surname><given-names>Y.W.</given-names></name>
</person-group><article-title>Apigenin, a dietary flavonoid, inhibits proliferation of human bladder cancer T-24 cells via blocking cell cycle progression and inducing apoptosis</article-title><source>Cancer Cell Int.</source><year>2015</year><volume>15</volume><fpage>33</fpage><pub-id pub-id-type="doi">10.1186/s12935-015-0186-0</pub-id><pub-id pub-id-type="pmid">25859163</pub-id>
</element-citation></ref><ref id="B41-toxics-13-00112"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Han</surname><given-names>T.</given-names></name>
<name><surname>Kang</surname><given-names>D.</given-names></name>
<name><surname>Ji</surname><given-names>D.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Zhan</surname><given-names>W.</given-names></name>
<name><surname>Fu</surname><given-names>M.</given-names></name>
<name><surname>Xin</surname><given-names>H.-B.</given-names></name>
<name><surname>Wang</surname><given-names>J.-B.</given-names></name>
</person-group><article-title>How does cancer cell metabolism affect tumor migration and invasion?</article-title><source>Cell Adh. Migr.</source><year>2013</year><volume>7</volume><fpage>395</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.4161/cam.26345</pub-id><pub-id pub-id-type="pmid">24131935</pub-id>
</element-citation></ref><ref id="B42-toxics-13-00112"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Erdogan</surname><given-names>S.</given-names></name>
<name><surname>Doganlar</surname><given-names>O.</given-names></name>
<name><surname>Doganlar</surname><given-names>Z.B.</given-names></name>
<name><surname>Serttas</surname><given-names>R.</given-names></name>
<name><surname>Turkekul</surname><given-names>K.</given-names></name>
<name><surname>Dibirdik</surname><given-names>I.</given-names></name>
<name><surname>Bilir</surname><given-names>A.</given-names></name>
</person-group><article-title>The flavonoid apigenin reduces prostate cancer CD44+ stem cell survival and migration through PI3K/Akt/NF-&#x003ba;B signaling</article-title><source>Life Sci.</source><year>2016</year><volume>162</volume><fpage>77</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2016.08.019</pub-id><pub-id pub-id-type="pmid">27569589</pub-id>
</element-citation></ref><ref id="B43-toxics-13-00112"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dai</surname><given-names>J.</given-names></name>
<name><surname>Van Wie</surname><given-names>P.G.</given-names></name>
<name><surname>Fai</surname><given-names>L.Y.</given-names></name>
<name><surname>Kim</surname><given-names>D.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Poyil</surname><given-names>P.</given-names></name>
<name><surname>Luo</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
</person-group><article-title>Downregulation of NEDD9 by apigenin suppresses migration, invasion, and metastasis of colorectal cancer cells</article-title><source>Toxicol. Appl. Pharmacol.</source><year>2016</year><volume>311</volume><fpage>106</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/j.taap.2016.09.016</pub-id><pub-id pub-id-type="pmid">27664007</pub-id>
</element-citation></ref><ref id="B44-toxics-13-00112"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qin</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>D.</given-names></name>
<name><surname>Zhou</surname><given-names>H.G.</given-names></name>
<name><surname>Wang</surname><given-names>X.H.</given-names></name>
<name><surname>Zhong</surname><given-names>W.L.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Gu</surname><given-names>W.G.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Zhang</surname><given-names>C.H.</given-names></name>
<name><surname>Liu</surname><given-names>Y.R.</given-names></name>
<etal/>
</person-group><article-title>Apigenin inhibits NF-kappaB and snail signaling, EMT and metastasis in human hepatocellular carcinoma</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>41421</fpage><lpage>41431</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.9404</pub-id><pub-id pub-id-type="pmid">27203387</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="toxics-13-00112-f001"><label>Figure 1</label><caption><p>The cytotoxicity effects of apigenin on MMNK1 immortalized human cholangiocyte and KKU-M055 human cholangiocarcinoma cells. The percentage of cell viability after apigenin treatments of 24 h (<bold>A</bold>) and 48 h (<bold>B</bold>) was calculated relative to the untreated control group. Data represent the mean &#x000b1; SD of three independent observations. <italic toggle="yes">p</italic> &#x0003c; 0.05 was considered statistically significant (* <italic toggle="yes">p</italic> &#x0003c; 0.05; ** <italic toggle="yes">p</italic> &#x0003c; 0.01).</p></caption><graphic xlink:href="toxics-13-00112-g001" position="float"/></fig><fig position="float" id="toxics-13-00112-f002"><label>Figure 2</label><caption><p>Effects of apigenin on cell cycle progression and apoptosis in KKU-M055 cells using flow cytometry. KKU-M055 cells were either untreated or treated with apigenin at IC50 concentrations for 24 h. (<bold>A</bold>) Representative histograms illustrating distribution of cell cycle phases. (<bold>B</bold>) Quantitative data representing percentage of cells in various cell cycle phases. (<bold>C</bold>) Apoptosis induction was examined using flow cytometry-based Annexin V and PI staining. (<bold>D</bold>) Quantitative data on apoptosis percentages in untreated and apigenin-treated cells. Data are shown as means &#x000b1; SD from three independent experiments. ** <italic toggle="yes">p</italic> &#x0003c; 0.01 indicates statistically significant differences.</p></caption><graphic xlink:href="toxics-13-00112-g002" position="float"/></fig><fig position="float" id="toxics-13-00112-f003"><label>Figure 3</label><caption><p>Apigenin-induced apoptosis characteristics and caspase activity in KKU-M055 cells. (<bold>A</bold>) Fluorescence micrographs showing Hoechst 33258 (first column) and Rho 123 (middle column) staining in untreated and apigenin-treated KKU-M055 cells. Morphological changes, including nuclear condensation and fragmentation, are indicated by white arrows. (<bold>B</bold>) Caspase activity induced by apigenin treatment, with activities of caspase-8, -9, and -3/7 assessed using luminescence assay. Values are expressed as mean &#x000b1; SD from three independent experiments. ** <italic toggle="yes">p</italic> &#x0003c; 0.01 are considered statistically significant. (<bold>C</bold>) Proposed mechanisms of apigenin-induced apoptosis in KKU-M055 cells, showing caspase cascade activation via both extrinsic and intrinsic pathways. The red arrows indicate an increase relative to the control, while the green arrows indicate a decrease relative to the control.</p></caption><graphic xlink:href="toxics-13-00112-g003" position="float"/></fig><fig position="float" id="toxics-13-00112-f004"><label>Figure 4</label><caption><p>Apigenin inhibits KKU-M055 migration. (<bold>A</bold>) Representative image showing effects of apigenin on cell migration, as assessed using Transwell migration assay. (<bold>B</bold>) Quantitative data showed significant reduction in number of migrating cells treated with apigenin compared to untreated control. Data are represented as mean &#x000b1; SD. ** <italic toggle="yes">p</italic> &#x0003c; 0.01 indicates statistically significant compared to control.</p></caption><graphic xlink:href="toxics-13-00112-g004" position="float"/></fig></floats-group></article>